Study With Phage for CF Subjects With Pseudomonas Lung Infection
← catalyst calendarSponsored by BiomX Ltd (industry) · PHGE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
63estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-02 | actual | When the study began enrolling |
| Primary completion | Mar 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Pseudomonas Aeruginosa Infection
- Cystic Fibrosis (CF)
Interventions
- Biological: BX004 — also filed as Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
- Other: Placebo — also filed as Nebulized placebo
Primary outcome
what the primary-completion date above is the date OFChange in sputum Pseudomonas aeruginosa (PsA) burden at 8 weeks (EOT)
measured 8 weeks
Permalink · PHGE's whole pipeline · Catalyst calendar · Every registered study · What changed